TAK-242 in Patients With Acute Alcoholic Hepatitis

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2021
A phase 2a double-blind, randomized, placebo-controlled, multicenter, proof-of-concept study to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of TAK-242 in subjects with acute decompensation of alcohol-related cirrhosis due to alcoholic hepatitis resulting in acute-on-chronic liver failure.
Epistemonikos ID: 976b7681cecd78ea79c6ca013eb0cd5a2a32cea4
First added on: May 07, 2024